PHARMAC complicates treatment of glaucoma
Haddad, P.
New Zealand Medical Journal 112(1099): 434
1999
ISSN/ISBN: 0028-8446 PMID: 10678231 Document Number: 500311
Document emailed within 1 workday
Related Documents
Rossetti, D. 1953: Studies on glaucoma. III. Glaucoma and the vegetative nervous system; glaucoma and endocrine secretions; glaucoma, allergy and stress; glaucoma and its therapy; conclusions Annali di Ottalmologia E Clinica Oculistica 79(11): 591-624Spaeth, G.L. 1999: Seven steps to assure the best possible treatment of persons with glaucoma or suspected of having glaucoma Oftalmologia 49(4): 19-34
Frothingham, R.; Blitchington, R.B.; Lee, D.H.; Greene, R.C.; Wilson, K.H. 1992: UV absorption complicates PCR decontamination Biotechniques 13(2): 208-210
Augustine, J.J. 2006: Cold, wet and hurt. Hypothermia complicates trauma when a hunter falls fom a tree Emergency Medical Services 35(12): 36; 38
Bennett, W.; McNee, W. 1998: PHARMAC and statins New Zealand Medical Journal 111(1077): 439-440
Metcalfe, S.; Moodie, P.; Davies, A.; McNee, W.; Dougherty, S. 2005: PHARMAC responds on salbutamol New Zealand Medical Journal 118(1221): U1644
Grocott, R.; Metcalfe, S.; Moodie, P. 2006: PHARMAC and erythropoietin for cancer patients New Zealand Medical Journal 119(1236): U2039
Baber, W.J.; Neeff, M. 2008: Ciproxin HC eardrops application for funding--and response from PHARMAC New Zealand medical journal 121(1281): 111-2; author reply 112-4
Metcalfe, S.; Wilkinson, T.; Rasiah, D. 2006: PHARMAC responds on agents to prevent osteoporotic fractures New Zealand Medical Journal 119(1230): U1895
Milne, R.; Wonder, M. 2011: Response to PHARMAC on Access to new medicines in New Zealand compared to Australia New Zealand Medical Journal 124(1347): 91-93
Metcalfe, S.; Moodie, P.; McNee, W. 2005: PHARMAC and tobacco control in New Zealand: two licensed funded options are already available New Zealand medical journal 118(1217): U1544; author reply U1544; discussion U1544
Grocott, R.; Metcalfe, S. 2012: PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric New Zealand Medical Journal 125(1358): 89-90
Grocott, R.; Metcalfe, S.; Alexander, P.; Werner, R. 2013: Assessing the value for money of pharmaceuticals in new Zealand--PHARMAC's approach to cost-utility analysis New Zealand Medical Journal 126(1378): 60-73
Pecora, J.L. 1979: Malignant glaucoma worsened by miotics in a postoperative angle-closure glaucoma patient Annals of Ophthalmology 11(9): 1412-1414
Tsvetkova, M.K.; Babushkin, A.E.; Kolesnikova, L.N. 1990: The effect of anti-glaucoma surgery on the visual function in patients with primary glaucoma Vestnik Oftalmologii 106(2): 3-5
Sothornwit, N. 2008: Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report Journal of the Medical Association of Thailand 91 Suppl. 1: S162-S165
Jilani, F.A.; Khan, A.M.; Kesharwani, R.K. 1987: Study of topical corticosteroid response in glaucoma suspects and family members of established glaucoma patients Indian Journal of Ophthalmology 35(3): 141-145
Bigger, J.F.; Becker, B. 1971: Cataracts and primary open-angle glaucoma: the effect of uncomplicated cataract extraction on glaucoma control Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology 75(2): 260-272
Dake, C.L. 1984: Argon-laser coagulation of the scleral spur (L.S.S.C.) in primary open-angle glaucoma and pigment glaucoma Bulletin de la Societe Belge d'Ophtalmologie 210: 3-10
Dubielowa, J. 1973: Acute attack of glaucoma in the non-operated eye following surgery for glaucoma in the contralateral eye Klinika Oczna 43(7): 789-792